Aura Biosciences

Aura Biosciences is a clinical-stage biopharmaceutical company committed to developing a new class of targeted oncology therapies. Their focus is on cancers with high unmet needs, aiming to establish a new standard of care for patients. Their innovative approach leverages a virus-like drug conjugate (VDC) technology platform.

The company's flagship VDC candidate, belzupacap sarotalocan (bel-sar), is being developed for the first-line treatment of early-stage choroidal melanoma, a rare and often vision-threatening cancer with no approved drug therapies. Aura is also exploring bel-sar for additional ocular oncology indications, including choroidal metastasis, as well as for bladder cancer, their first non-ocular solid tumor indication.

Aura Biosciences is a clinical-stage biotechnology company dedicated to developing a new class of targeted oncology therapies. Their mission is to create innovative treatments that deliver meaningful therapeutic benefits to patients with cancer indications that have high unmet needs. This includes creating a new standard of care for ocular and urologic cancers, with a particular focus on choroidal melanoma. The company's passion for science and its unwavering commitment to patients are driving forces behind their efforts to pioneer these new cancer therapies.

Aura Biosciences fosters a collaborative and passionate culture where individuals are encouraged to grow and contribute to the company's mission of developing novel cancer therapies. The company values teamwork, expertise sharing, and a commitment to science, as evidenced by employee testimonials highlighting the collaborative environment, passion for innovation, and the opportunity to learn and develop new skills.